IRIS Accounts Production v24.3.0.553 03357037 Board of Directors 1.4.23 31.3.24 31.3.24 0 0 false true false false true false Fair value model iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh033570372023-03-31033570372024-03-31033570372023-04-012024-03-31033570372022-03-31033570372022-04-012023-03-31033570372023-03-3103357037ns15:EnglandWales2023-04-012024-03-3103357037ns14:PoundSterling2023-04-012024-03-3103357037ns10:Director12023-04-012024-03-3103357037ns10:PrivateLimitedCompanyLtd2023-04-012024-03-3103357037ns10:SmallEntities2023-04-012024-03-3103357037ns10:AuditExempt-NoAccountantsReport2023-04-012024-03-3103357037ns10:SmallCompaniesRegimeForDirectorsReport2023-04-012024-03-3103357037ns10:SmallCompaniesRegimeForAccounts2023-04-012024-03-3103357037ns10:FullAccounts2023-04-012024-03-3103357037ns10:Director22023-04-012024-03-3103357037ns10:RegisteredOffice2023-04-012024-03-3103357037ns5:CurrentFinancialInstruments2024-03-3103357037ns5:CurrentFinancialInstruments2023-03-3103357037ns5:ShareCapital2024-03-3103357037ns5:ShareCapital2023-03-3103357037ns5:FurtherSpecificReserve1ComponentTotalEquity2024-03-3103357037ns5:FurtherSpecificReserve1ComponentTotalEquity2023-03-3103357037ns5:RetainedEarningsAccumulatedLosses2024-03-3103357037ns5:RetainedEarningsAccumulatedLosses2023-03-3103357037ns5:ComputerEquipment2023-04-012024-03-3103357037ns5:ComputerEquipment2023-03-3103357037ns5:ComputerEquipment2024-03-3103357037ns5:ComputerEquipment2023-03-3103357037ns5:WithinOneYearns5:CurrentFinancialInstruments2024-03-3103357037ns5:WithinOneYearns5:CurrentFinancialInstruments2023-03-3103357037ns5:DeferredTaxation2023-03-3103357037ns5:DeferredTaxation2024-03-31
REGISTERED NUMBER: 03357037 (England and Wales)












MEDIBUILD LIMITED

UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2024






MEDIBUILD LIMITED (REGISTERED NUMBER: 03357037)

CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024










Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


MEDIBUILD LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 31 MARCH 2024







DIRECTORS: M W Gregory
Mrs C C Domone



REGISTERED OFFICE: Highland House
Mayflower Close
Chandlers Ford
Eastleigh
Hampshire
SO53 4AR



REGISTERED NUMBER: 03357037 (England and Wales)



BANKERS: National Westminster Bank plc
105 High Street
Winchester
Hampshire
SO23 9AW

MEDIBUILD LIMITED (REGISTERED NUMBER: 03357037)

BALANCE SHEET
31 MARCH 2024

2024 2023
Notes £ £
FIXED ASSETS
Tangible assets 4 424 1,117
Investment property 5 1,250,000 1,250,000
1,250,424 1,251,117

CURRENT ASSETS
Debtors 6 8,538 8,538
Cash at bank and in hand 116,273 71,424
124,811 79,962
CREDITORS
Amounts falling due within one year 7 (95,362 ) (118,908 )
NET CURRENT ASSETS/(LIABILITIES) 29,449 (38,946 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,279,873

1,212,171

PROVISIONS FOR LIABILITIES 8 (85,952 ) (85,952 )
NET ASSETS 1,193,921 1,126,219

CAPITAL AND RESERVES
Called up share capital 100 100
Unrealised reserves 633,706 633,706
Retained earnings 560,115 492,413
SHAREHOLDERS' FUNDS 1,193,921 1,126,219

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

MEDIBUILD LIMITED (REGISTERED NUMBER: 03357037)

BALANCE SHEET - continued
31 MARCH 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 1 November 2024 and were signed on its behalf by:





M W Gregory - Director


MEDIBUILD LIMITED (REGISTERED NUMBER: 03357037)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 MARCH 2024


1. STATUTORY INFORMATION

Medibuild Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with FRS 102 "The Financial Reporting Standards applicable in the UK and Republic of Ireland" ("FRS 102") and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies' regime.

The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include certain financial instruments at fair value. The principal accounting policies adopted are set out below.

Turnover
The turnover shown in the profit and loss account represents rent receivable, exclusive of value added tax.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life.
Computer equipment - Straight line over 3 years

The gain or loss arising on disposal of an asset is determined as the difference between the sales proceeds and the carrying value of the asset and is recognised in the income statement.

Investment property
Investment property is shown at most recent valuation. Any aggregate surplus or deficit arising from changes in fair value is recognised in profit or loss.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

MEDIBUILD LIMITED (REGISTERED NUMBER: 03357037)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


2. ACCOUNTING POLICIES - continued

Financial assets
Basic financial assets, which include trade and other receivables and cash and bank balances are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method.

Financial liabilities
Basic financial liabilities, which include trade and other payables, are initially measured at transaction price and subsequently measured at amortised cost.

Equity instruments
Equity instruments issued by the company are recorded at the fair value of the proceeds received net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was NIL (2023 - NIL).

4. TANGIBLE FIXED ASSETS
Computer
equipment
£
COST
At 1 April 2023
and 31 March 2024 2,724
DEPRECIATION
At 1 April 2023 1,607
Charge for year 693
At 31 March 2024 2,300
NET BOOK VALUE
At 31 March 2024 424
At 31 March 2023 1,117

5. INVESTMENT PROPERTY
Total
£
FAIR VALUE
At 1 April 2023
and 31 March 2024 1,250,000
NET BOOK VALUE
At 31 March 2024 1,250,000
At 31 March 2023 1,250,000

MEDIBUILD LIMITED (REGISTERED NUMBER: 03357037)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


5. INVESTMENT PROPERTY - continued

Fair value at 31 March 2024 is represented by:
£
Valuation in 1999 74,479
Valuation in 2003 343,000
Valuation in 2005 65,000
Valuation in 2006 100,000
Valuation in 2007 60,000
Valuation in 2008 (65,000 )
Valuation in 2009 25,000
Valuation in 2021 115,000
Cost 532,521
1,250,000

If the investment property had not been revalued it would have been included at the following historical cost:

2024 2023
£ £
Cost 532,521 532,521

The investment property was valued on an open market basis on 31 March 2024 by the directors of the company .

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Trade debtors 8,538 8,538

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Taxation and social security 23,123 26,734
Other creditors 72,239 92,174
95,362 118,908

8. PROVISIONS FOR LIABILITIES
2024 2023
£ £
Deferred tax 85,952 85,952

Deferred tax
£
Balance at 1 April 2023 85,952
Balance at 31 March 2024 85,952

MEDIBUILD LIMITED (REGISTERED NUMBER: 03357037)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 31 MARCH 2024


8. PROVISIONS FOR LIABILITIES - continued

Deferred tax has been calculated at the substantively enacted main corporation tax rate, which at 31 March 2024 was 25% (2023 - 25%).